Vitreoretinal Surgery Devices Market Analysis

Vitreoretinal Surgery Devices Market Analysis

The photocoagulation lasers segment in the vitreoretinal surgery devices market exceeded USD 479 million in 2021. Photocoagulation lasers are applied in the treatment several eye disorders such the two leading causes of blindness in the U.S. including diabetic retinopathy and age-related macular degeneration. These precise laser-sourced devices reduce the risk of vision loss by cauterizing ocular blood vessels.

The vitreoretinal surgery devices market for ambulatory surgery centres segment is estimated to reach USD 374 million by 2028 owing to the growing number of vitreoretinal surgeries at ambulatory surgical centers. The increased usage of advanced and miniaturized vitreoretinal surgery devices reduced surgical time & increased convenience, and reduced instances of complications have minimized the requirement for hospitalization.
 

Due to these developments, the number of vitreoretinal surgeries conducted in an outpatient setting has surged steadily that is expected to benefit the market share. In addition to this, the increasing pressure to minimize surging healthcare costs and availability of efficient equipment that limit the surgical complications including the reduced risks of catching the retina is further set to spur the industry demand.
 

U.S. vitreoretinal surgery devices market is slated to cross USD 815 million by 2028 on account of the high acceptance of advanced devices and the rise in incidence of eye-related disorders that translates to increased vitreoretinal surgeries across the country. For instance, according to the Centers for Disease Control & Prevention statistics, an estimated 20.5 million citizens in the U.S. aged 40 years and above were suffering with cataract in one or both eyes, and around 6.1 million Americans had their lens removed surgically.
 

The overall number of individuals with cataracts was further projected to reach to 30.1 million by 2020. Similarly, approximately 1.8 million Americans aged 40 years and above were affected by age-related macular degeneration (AMD) and an additional 7.3 million Americans are at considerable risk of developing AMD. Such adverse conditions along with aging population are predicted to impel the adoption rate of vitreoretinal surgery devices in the country.